Leishmaniasis Treatment Using Triazole-phtalimides As Chemotherapeutic Agents

The different clinical forms of leishmaniasis (cutaneous, mucocutaneous, and visceral) share a common treatment approach involving toxic chemotherapy and serious side effects, leading to the development of treatment resistance. Thus, the search for more specific drugs against parasites, without causing harm to the host, is still needed.

The technology relies on the use of molecules containing the compounds triazole and phthalimide, obtained through a cheap and high-yield method, as leishmanicidal agents for the treatment of leishmaniasis. The combination of molecules with different modes of action into a single chemical entity can reduce the side effects and the emergence of resistance, observed in conventional medications against leishmaniasis.

Partners to advance through the stages of pre-clinical and clinical studies of the technology and in obtaining the molecule on a large scale.